Inhibitory receptor acting as a major negative regulator of T-cell responses (PubMed:11279501, PubMed:11279502, PubMed:16551244, PubMed:1714933, PubMed:18641304, PubMed:28484017). Acts as a decoy receptor: the affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28 (PubMed:11279501, PubMed:11279502, PubMed:16551244, PubMed:1714933, PubMed:28484017)
Homodimer; disulfide-linked (PubMed:11279501, PubMed:11279502, PubMed:21156796, PubMed:28484017, Ref.24). Interacts with ICOSLG (PubMed:28484017)
Widely expressed with highest levels in lymphoid tissues. Detected in activated T-cells where expression levels are 30- to 50-fold less than CD28, the stimulatory coreceptor, on the cell surface following activation
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical features are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.
A multifactorial, chronic disorder of the small intestine caused by intolerance to gluten. It is characterized by immune-mediated enteropathy associated with failed intestinal absorption, and malnutrition. In predisposed individuals, the ingestion of gluten-containing food such as wheat and rye induces a flat jejunal mucosa with infiltration of lymphocytes.
An autosomal dominant primary immunodeficiency characterized by severe autoimmunity, infiltration of non-lymphoid organs, such as the intestine, lungs and brain, by hyperactive T cells and B cells, autoimmune cytopenias, and hypogammaglobulinemia in early childhood.
Click a pathway to open the interactive Reactome viewer.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to CTLA4, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 266
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT02705482 | Select Advanced Solid Tumors | A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors | PHASE1 | COMPLETED |
| NCT03013491 | Solid Tumor, Lymphoma | PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas | PHASE1, PHASE2 | TERMINATED |
| NCT03426189 | HIV-1-infection | HIV Persistence in Lymph Node and Peripheral Blood | N/A | COMPLETED |
| NCT05792735 | Locally Advanced Rectal Carcinoma | Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer | PHASE2 | COMPLETED |
| NCT01445379 | Sarcoma, Wilm's Tumor, Lymphoma, Neuroblastoma | Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer | PHASE1 | COMPLETED |
| NCT03249142 | Ovarian Cancer | Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer | PHASE1, PHASE2 | COMPLETED |
| NCT06173505 | Nonsquamous Non-small Cell Lung Cancer | Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC | PHASE1, PHASE2 | TERMINATED |
| NCT04572152 | Advanced or Metastatic Solid Tumors | A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors | PHASE1 | COMPLETED |
| NCT06542549 | Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody), Chemotherapy, Efficacy, Safety | Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer | PHASE3 | NOT_YET_RECRUITING |
| NCT05773105 | Advanced Hepatocellular Carcinoma | A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC | PHASE1, PHASE2 | UNKNOWN |